GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (OTCPK:RSLS) » Definitions » Graham Number

Reshape Lifesciences (Reshape Lifesciences) Graham Number : $N/A (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Reshape Lifesciences Graham Number?

Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.

As of today (2024-04-28), the stock price of Reshape Lifesciences is $2.76. Reshape Lifesciences's graham number for the quarter that ended in Dec. 2023 was $N/A. Therefore, Reshape Lifesciences's Price to Graham Number ratio for today is N/A.

The historical rank and industry rank for Reshape Lifesciences's Graham Number or its related term are showing as below:

RSLS's Price-to-Graham-Number is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.82
* Ranked among companies with meaningful Price-to-Graham-Number only.

Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.


Reshape Lifesciences Graham Number Historical Data

The historical data trend for Reshape Lifesciences's Graham Number can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences Graham Number Chart

Reshape Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Graham Number
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Reshape Lifesciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Graham Number Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Reshape Lifesciences's Graham Number

For the Medical Devices subindustry, Reshape Lifesciences's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reshape Lifesciences's Price-to-Graham-Number Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's Price-to-Graham-Number distribution charts can be found below:

* The bar in red indicates where Reshape Lifesciences's Price-to-Graham-Number falls into.



Reshape Lifesciences Graham Number Calculation

Graham Number is a concept based on Ben Graham's conservative valuation of companies.

Reshape Lifesciences's Graham Number for the fiscal year that ended in Dec. 2023 is calculated as

Graham Number
=sqrt of (22.5* Tangible Book per Share *EPS without NRI)
=sqrt of (22.5*1.081*0)
=N/A

Reshape Lifesciences's Graham Number for the quarter that ended in Dec. 2023 is calculated as

Graham Number
=sqrt of (22.5*Tangible Book per Share*EPS without NRI (TTM))
=sqrt of (22.5*1.904*0)
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reshape Lifesciences  (OTCPK:RSLS) Graham Number Explanation

Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:

Current price should not be more than 15 times average earnings of the past three years.

Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)

Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.

In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.

Reshape Lifesciences's Price to Graham number Ratio for today is calculated as

Price to Graham number=Share Price (Today)/Graham number (Q: Dec. 2023 )
=2.76/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Please keep these in mind:

1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.


Reshape Lifesciences Graham Number Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.


Reshape Lifesciences (Reshape Lifesciences) Business Description

Traded in Other Exchanges
Address
1001 Calle Amanecer, San Clemente, CA, USA, 92673
Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
Executives
Thomas Stankovich officer: Chief Financial Officer 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Barton P. Bandy officer: President and CEO 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Dan W Gladney director, officer: Chairman, President and CEO 2800 PATTON ROAD, ST. PAUL MN 55113
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Sabby Management, Llc 10 percent owner 115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Arda Phd Minocherhomjee director C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606
Scott P Youngstrom officer: CFO and SVP, Finance 2800 PATTON ROAD ST. PAUL MN 55113
Joseph Patrick Healey 10 percent owner 31 HUDSON YARDS, 10TH FLOOR, NEW YORK NY 10001
Healthcor Partners Ii, L.p. 10 percent owner 152 W. 57TH STREET, 43RD FLOOR NEW YORK NY 10019
Michael Y Mashaal director 309 WAVERLEY OAKS RD., SUITE 105 WALTHAM MA 02452
Healthcor Partners Fund Ii, L.p. 10 percent owner CARNEGIE HILL TOWER 152 WEST 57TH STREET, 43RD FLOOR NEW YORK NY 10019
Jeffrey C Lightcap 10 percent owner 152 W 57TH STREET 43RD FLOOR, NEW YORK NY 10019
Healthcor Partners Management Gp, Llc 10 percent owner 152 W 57TH STREET 43RD FLOOR, NEW YORK NY 10019

Reshape Lifesciences (Reshape Lifesciences) Headlines

From GuruFocus